Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $302,965.50 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 11,881 shares of the business’s stock in a transaction that occurred on Tuesday, October 13th. The shares were sold at an average price of $25.50, for a total value of $302,965.50. Following the completion of the sale, the chief operating officer owned 377,802 shares of the company’s stock, valued at $9,633,951. This trade represents a 3.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

• On Thursday, October 8th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.66, for a total value of $304,866.46.
• On Monday, October 5th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $29.19, for a total value of $346,806.39.
• On Friday, October 2nd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $28.13, for a total value of $334,212.53.

Adaptive Biotechnologies Stock Performance

Adaptive Biotechnologies stock opened at $25.58 on Friday. The company has a fifty day moving average price of $26.18 and a two-hundred day moving average price of $20.46. The company has a quick ratio of 4.68, a current ratio of 4.79 and a debt-to-equity ratio of 2.22. Adaptive Biotechnologies Corporation has a 12 month low of $12.00 and a 12 month high of $30.74.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The business had revenue of $71.55 million for the quarter, compared to the consensus estimate of $65.44 million. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The firm’s revenue for the quarter was up 21.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.17) EPS. On average, equities analysts anticipate that Adaptive Biotechnologies Corporation will post -0.40 earnings per share for the current fiscal year.

Institutional Trading of Adaptive Biotechnologies

Hedge funds have recently bought and sold shares of the company. Tidal Investments LLC acquired a new position in Adaptive Biotechnologies during the 2nd quarter valued at about $855,000. Integrated Wealth Concepts LLC bought a new position in Adaptive Biotechnologies in the 2nd quarter worth about $46,000. Arizona State Retirement System grew its position in Adaptive Biotechnologies by 1.3% in the 2nd quarter. Arizona State Retirement System now owns 31,866 shares of the company’s stock worth $684,000 after purchasing an additional 416 shares during the last quarter. Nykredit A S bought a new position in Adaptive Biotechnologies in the 2nd quarter worth about $31,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Adaptive Biotechnologies in the second quarter valued at approximately $754,000. 99.17% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ADPT has been the subject of a number of recent research reports. The Goldman Sachs Group started coverage on shares of Adaptive Biotechnologies in a research report on Tuesday, September 29th. They set a “buy” rating and a $35.00 price objective for the company. National Bank Financial set a $34.00 price objective on shares of Adaptive Biotechnologies in a research note on Tuesday, September 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Friday, July 17th. BTIG Research lifted their target price on Adaptive Biotechnologies from $25.00 to $34.00 and gave the company a “buy” rating in a research note on Tuesday, September 22nd. Finally, TD Cowen upped their target price on Adaptive Biotechnologies from $28.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $30.06.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and therapeutic applications. Its technologies analyze immune-cell receptors, including T-cell and B-cell receptors, to help identify and measure immune responses associated with cancer, infectious diseases and other conditions.

The company’s product portfolio includes immunoSEQ, a research and clinical platform for immune-repertoire sequencing, and clonoSEQ, a diagnostic test used to detect and monitor measurable residual disease in certain blood cancers.